Immunohistochemical hepatocytes nuclear test for the evaluation of responses to treatment of the chronic hepatitis C by interferon alpha.
The results of the microscopic examinations on 23 paired liver biopsies of patients affected by the chronic hepatitis C, were realized successively before and after treatment by interferon alpha during six months. They showed a particular interest in the use of the antibody Anticore. The other antibody Anti C100-3-clone Tordji 32, was partially associated with the Anticore to improve its total number of positive responses by interchanging the loss of 3 wrong positive numbers (-) of the same patients from the Anticore, against earnings of 3 wrong negative numbers (+) for the same patients from the Anti C100-3-clone 32. This operation led to 70% of sensitivity. The results were submitted to mathematical verification and allowed to look for the maximum of the predictive probabilities. As for the other antibody Anti C100-3-Tordji-clone 22, it only used as a witness for some positive values. Moreover, this work brought a practical implementation to solve the problem concerning the indeterminate responses. Elsewhere, it appeared plausible for the Anticore to advance beyond its value, if the improvement of its conditions of realization were requiring. That hope was reasonable since it was yielded from the results of the predictive equations of the likelihood ratios by the logistic regression method which built two mathematical models to comparison for confirmation.
Cherid
A
A
Cellular and Metabolic Pathology of Liver, INSERM U559, Faculty of Medicine, 13385 Marseille Cedex 05, France.
Cherid
N
N
Chamlian
V
V
Boutaghou
H O
HO
Chamlian
A
A
D016208:Databases, Factual; D005455:Fluorescent Antibody Technique; D018937:Hepatitis C Antibodies; D019698:Hepatitis C, Chronic / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D022781:Hepatocytes / Q000187:drug effects* / Q000473:pathology* / Q000821:virology; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D007370:Interferon Type I / Q000627:therapeutic use*; D016013:Likelihood Functions; D008954:Models, Biological; D016011:Normal Distribution; D011994:Recombinant Proteins
D018937:Hepatitis C Antibodies; D007370:Interferon Type I; D011994:Recombinant Proteins; C078224:anti-C100-3